Novel Targets to Prevent Borrelia burgdorferi Infection and Lyme Disease


B. burgdorferi-infected ticks can cause Lyme disease in mammalian hosts. This technology relates to the use of B. burgdorferi outer surface proteins (BBA64 and BBA66) as Lyme disease vaccine candidates. In vivo animal studies demonstrate these outer surface proteins inhibit tick-to-host B. burgdorferi transmission. Presently, there is no vaccine approved for Lyme disease.

Potential Commercial Applications: Competitive Advantages:
  • B. burgdorferi/Lyme disease vaccine development
  • B. burgdorferi diagnostics
  • Prevention of B. burgdorferi infection by passive immunity
  • Zoonotic/tick-borne disease surveillance
  • Public health vaccination programs against Lyme disease
 
  • Currently no approved Lyme disease vaccines


Development Stage:
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)


Inventors:

Robert Gilmore (CDC)  ➽ more inventions...


Intellectual Property:
US Application No. 61/814,741

Publications:
Patton TG, et al. PMID 23630963
Brandt KS, et al. PMID 24501342
Patton TG, et al. PMID 21559293
Gilmore RD Jr, et al. PMID 20368453
Gilmore RD Jr, et al. PMID 18848981
Gilmore RD Jr, et al. PMID 17371862

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-573-2013-0
Updated: Feb 10, 2014